The global antiplatelet drugs market size attained a value of USD 2.2 billion in 2022 driven by the advancements in the pharmaceutical industry and the increasing cases of thrombosis, both arterial and venous. The market is anticipated to grow at a CAGR of 7.8% during the forecast period of 2023-2031 to attain a value of USD 4.2 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is the leading region in the global market for antiplatelet drugs. The region accounts for a significant share in the industry owing to the increasing penetration of key players in the region and the growing investments in clinical trials for antiplatelet drugs. Further, the presence of a large number of patients suffering from myocardial infarction and ischaemic strokes across the region is also aiding the industry growth. In the United States, around 800,000 individuals suffer from stroke every year, out of which 87% are ischaemic strokes. Thus, the growing prevalence of these diseases is leading to an increased demand for antiplatelet drugs. Meanwhile, the Asia Pacific is expected to witness a robust growth over the forecast period owing to the rising investments in R&D activities and the increasing government initiatives to reduce the number of deaths caused by thrombotic cardiovascular disease.
Antiplatelet drug belongs to a class of pharmaceuticals that decrease platelet aggregation, thus, preventing the formation of thrombus. These drugs are often referred to as platelet aggregation inhibitors. They help prevent blood cells (platelets) from clumping together to form a clot, thereby, decreasing the formation of potentially harmful blood clots. They show high efficacy in the arterial circulation, where anticoagulants are less effective. Antiplatelet drugs are most commonly used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By drug, the market is divided into:
On the basis of drug class, the industry can be segmented into:
Based on applications, the industry can be categorised into:
The different routes of administration of antiplatelet drugs are:
The various distribution channels of the product are:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for antiplatelet drugs is being driven by the advancements in the pharmaceutical industry and the increasing cases of thrombosis, both arterial and venous. The incidences of venous thrombosis have escalated rapidly in the twenty-first century. Further, in patients with certain medical conditions, prevention and treatment of arterial thrombosis is particularly essential, as it can increase the chances of thrombosis or thromboembolism, which may lead to heart attack, pulmonary embolism, or stroke. Treatment of established arterial thrombosis involves the utilisation of antiplatelet drugs and thrombolytic therapy. These drugs are also essential for an individual who has undergone a heart surgery (especially prosthetic replacement heart valve). Thus, an increase in the number of patients undergoing heart surgery is also aiding the market growth. Other factors like increasing sedentary lifestyles, the proliferation of anticoagulant/antithrombotic drugs, rising geriatric population, and favourable government initiatives are further propelling the industry forward. Over the forecast period, the increasing R&D activities are expected to further contribute to the industry growth.
The report gives a detailed analysis of the following key players in the global antiplatelet drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug||
|Breakup by Drug Class||
|Breakup by Application||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Antiplatelet Drugs Market Overview
3.1 Global Antiplatelet Drugs Market Historical Value (2016-2022)
3.2 Global Antiplatelet Drugs Market Forecast Value (2023-2031)
4 Global Antiplatelet Drugs Market Landscape
4.1 Global Antiplatelet Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Antiplatelet Drugs Product Landscape
4.2.1 Analysis by Drug
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Application
4.2.4 Analysis by Route of Application
4.2.5 Analysis by Distribution Channel
5 Global Antiplatelet Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Antiplatelet Drugs Market Segmentation
6.1 Global Antiplatelet Drugs Market by Drug
6.1.1 Market Overview
6.2 Global Antiplatelet Drugs Market by Drug Class
6.2.1 Market Overview
6.2.2 Platelet Aggregation Inhibitors
6.2.3 Glycoprotein Platelet Inhibitors
6.2.4 Protease-Activated Receptor-1 Antagonists
6.3 Global Antiplatelet Drugs Market by Application
6.3.1 Market Overview
6.3.2 Myocardial Infraction
6.3.3 Percutaneous Coronary Interventions
6.3.5 Arterial Thrombosis
6.3.6 Dental Surgeries
6.4 Global Antiplatelet Drugs Market by Route of Administration
6.4.1 Market Overview
6.5 Global Antiplatelet Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.6 Global Antiplatelet Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Antiplatelet Drugs Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Antiplatelet Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Antiplatelet Drugs Market
9.1 Market Share by Country
10 Latin America Antiplatelet Drugs Market
10.1 Market Share by Country
11 Middle East and Africa Antiplatelet Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Supplier Landscape
18.1 Glenmark Pharmaceuticals Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Sanofi SA
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Pfizer Inc.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Baxter International Inc.
18.4.1 Financial Analysis
18.4.2 Financial Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5 Bayer AG
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 F. Hoffmann-La Roche Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7 Teva Pharmaceutical Industries Ltd.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 Mylan N.V.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9 Bausch Health Companies Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10 Johnson & Johnson Private Limited
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.11 Bristol-Myers Squibb Company
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.12 DAIICHI SANKYO COMPANY, LIMITED
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.13 Otsuka America Pharmaceutical, Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.14 Eli Lilly and Company
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.15 AbbVie Inc.
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.16 Genentech, Inc.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisitions
19 Global Antiplatelet Drugs Market - Distribution Model (Additional Insight)
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
Globally, Antiplatelet Drugs market reached a value of USD 2.2 billion in 2022.
The market is projected to expand at a CAGR of 7.8% from 2022 to 2031, growing to USD 4.2 billion by 2031.
The major drivers of the industry, such as the advancements in the pharmaceutical sector, increasing prevalence of thrombotic cardiovascular disease, increasing geriatric population, proliferation of anticoagulant/antithrombotic drugs, favourable government initiatives, and busy lifestyles, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the growing investments by the key players in the research and development of antiplatelet drugs.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading drugs in the market are aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole, ticlopidine, abciximab, and tirofiban, among others.
The major drug classes in the industry are platelet aggregation inhibitors, glycoprotein platelet inhibitors, and protease-activated receptor-1 antagonists, among others.
The significant application segments in the market are myocardial infraction, percutaneous coronary interventions, angioplasty, arterial thrombosis, and dental surgeries, among others.
The leading routes of administration of antiplatelet drugs in the industry are oral and injectable.
The major distribution channels in the market are hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The major players in the industry are Glenmark Pharmaceuticals Ltd., Sanofi SA, Pfizer Inc., Baxter International Inc., and Bayer AG, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.